Sorafenib is being studied in combination with cytotoxic chemotherapeutic agents, such as doxorubicin in melanoma where, despite a high frequency of BRAF mutations, this agent does not appear to be majorly biologically active (Richly et al, 2006). Here, BRAF is linked to melanoma.